{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:42:12Z","timestamp":1793904132888,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jbo.2026.100806","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:13:46Z","timestamp":1791389626000},"page":"100806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy of immune-oncology combinations versus sunitinib in patients with bone metastases from renal cell carcinoma: A systematic review and meta-analysis of phase III trials with long-term follow-up"],"prefix":"10.1016","volume":"61","author":[{"given":"Clara Fish Araujo","family":"de Albuquerque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila Caroline Souza","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza Del Fiol","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Elisa Saragossa","family":"Zafalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Theresa Zuffo","family":"Yabrude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2026.100806_bb0005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal Cell Carcinoma: A Review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jbo.2026.100806_bb0010","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2026.100806_bb0015","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"KEYNOTE-426 investigators, Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2026.100806_bb0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2026.100806_bb0025","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2026.100806_bb0030","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Electronic address: clinicalguidelines@esmo.org, renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2026.100806_bb0035","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"The 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2026.100806_bb0040","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1200\/JCO.23.01977","article-title":"Management of metastatic renal clear cell cancer: ASCO guideline rapid recommendation update","volume":"41","author":"Singer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100806_bb0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"Kidney cancer, version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.jbo.2026.100806_bb0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.10.023","article-title":"Prognosis of renal cell carcinoma with bone metastases: experience from a large cancer Centre","volume":"107","author":"Ruatta","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2026.100806_bb0055","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2026.100806_bb0060","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2026.100806_bb0065","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1158\/2767-9764.CRC-24-0304","article-title":"Antiangiogenic tyrosine kinase inhibitors have differential efficacy in clear cell renal cell carcinoma in bone","volume":"4","author":"Maksimovic","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jbo.2026.100806_bb0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00432-009-0664-7","article-title":"Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases","volume":"136","author":"Zo\u0142nierek","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100806_bb0075","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2026.100806_bb0080","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.7150\/jca.113258","article-title":"Tyrosine kinase inhibitors outperform immune checkpoint inhibitors in bone-predominant metastatic renal cell carcinoma: a multicenter real-world analysis","volume":"16","author":"Meng","year":"2025","journal-title":"J. Cancer"},{"key":"10.1016\/j.jbo.2026.100806_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jbo.2026.100806_bb0090","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ijc.35288","article-title":"Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: post hoc analysis of the CLEAR trial","volume":"156","author":"Gr\u00fcnwald","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbo.2026.100806_bb0095","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2026.44.16_suppl.4528","article-title":"Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: updated subgroup analysis of the phase 3 CheckMate-9ER trial","volume":"44","author":"Apolo","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100806_bb0100","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2026.100806_bb0105","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"143","article-title":"Choosing effect measures and computing estimates of effect","author":"Higgins","year":"2019"},{"key":"10.1016\/j.jbo.2026.100806_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.jbo.2026.100806_bb0115","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.jbo.2026.100806_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-33198-x","article-title":"Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma","volume":"16","author":"Toyoda","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbo.2026.100806_bb0125","doi-asserted-by":"crossref","first-page":"e16513","DOI":"10.1200\/JCO.2024.42.16_suppl.e16513","article-title":"Site of metastasis and clinical outcomes in patients with advanced renal cell carcinoma treated with TKI monotherapy or combination therapy: a real-world analysis","volume":"42","author":"Nuvola","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100806_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2026.06.003","article-title":"First-line therapy for metastatic renal cell carcinoma: an updated network meta-analysis using final follow-up data","author":"Yanagisawa","year":"2026","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.jbo.2026.100806_bb0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbo.2026.100806_bb0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11914-017-0378-8","article-title":"Hypoxia and bone metastatic disease","volume":"15","author":"Johnson","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.jbo.2026.100806_bb0145","article-title":"Invasion and metastasis in cancer: molecular insights and therapeutic targets","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jbo.2026.100806_bb0150","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8970173","article-title":"Immune checkpoint inhibitor therapy for bone metastases: specific microenvironment and current situation","author":"Liu","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jbo.2026.100806_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2026.102654","article-title":"Assessment of bone metastases, skeletal-related events and bone-targeting agents in patients with metastatic renal cell carcinoma receiving first-line systemic therapy (Meet-URO 33 study subanalysis)","author":"Valsecchi","year":"2026","journal-title":"Clin. Genitourin. Cancer"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:00:01Z","timestamp":1793901601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137426000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":31,"alternative-id":["S2212137426000680"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100806","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of immune-oncology combinations versus sunitinib in patients with bone metastases from renal cell carcinoma: A systematic review and meta-analysis of phase III trials with long-term follow-up","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100806"}}